| 國立成功大學 |
2023 |
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
|
Sequist, L.V.;Yang, J.C.-H.;Yamamoto, N.;O'Byrne, K.;Hirsh, V.;Mok, T.;Geater, S.L.;Orlov, S.;Tsai, C.-M.;Boyer, M.;Su, W.-C.;Bennouna, J.;Kato, T.;Gorbunova, V.;Lee, K.H.;Shah, R.;Massey, D.;Zazulina, V.;Shahidi, M.;Schuler, M. |
| 國立成功大學 |
2023 |
Bis(4-glycosyloxybenzyl) 2-isobutyltartrate and dihydrophenanthrene derivatives from the pseudobulbs of Pholidota chinensis and their anti-inflammatory activity
|
Tsai, C.-M.;Chen, Chen C.-Y.;Le, P.K.;Wang, Y.-H.;Lam, S.-H. |
| 臺大學術典藏 |
2022-09-20T07:56:46Z |
A Story of Two Tales: Behcet Disease Related Severe Aortic Regurgitation and Bacterial Endocarditis Associated Severe Mitral Regurgitation
|
Chang H.-Y.; Wang C.-H.; Tsai C.-M.; Enriquez-Sarano M.; Mankad R.; LI-TAN YANG |
| 臺大學術典藏 |
2022-06-27T07:07:39Z |
Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study
|
Fan W.-C.; CHONG-JEN YU; Tsai C.-M.; Huang M.-S.; Lai C.-L.; Hsia T.-C.; Tien Y.-J.; Huang S.-F.; Wu C.-H.; Chou K.-T.; Lee Y.-C.; Perng R.-P.; Chen Y.-M. |
| 臺大學術典藏 |
2022-06-27T07:06:34Z |
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients
|
Chang G.-C.; Tsai C.-M.; Chen K.-C.; CHONG-JEN YU; Shih J.-Y.; Yang T.-Y.; Lin C.-P.; Hsu J.-Y.; Chiu C.-H.; Perng R.-P.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2022-06-27T07:06:32Z |
Revisit of 1997 TNM staging system - Survival analysis of 1112 lung cancer patients in Taiwan
|
Perng R.-P.; Chen C.-Y.; Chang G.-C.; Hsia T.-C.; Hsu N.-Y.; Tsai Y.-H.; Tsai C.-M.; Yang C.-H.; Chen Y.-M.; CHONG-JEN YU; Lee J.-J.; Hsu H.-S.; Yu C.-T.; Kao E.-L.; Chiu C.-H. |
| 臺大學術典藏 |
2022-06-27T07:06:31Z |
A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma
|
Chen Y.-M.; CHONG-JEN YU; Yang C.-H.; Perng R.-P.; Tsai C.-M.; Shih J.-F.; Cheng A.-L.; Lefresne F.; Barbier M.; Pouget J.-C.; Yang P.-C. |
| 臺大學術典藏 |
2022-06-27T07:02:08Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; CHONG-JEN YU; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; Yang P.-C.; Miller V.A. |
| 臺大學術典藏 |
2022-06-27T07:01:36Z |
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: A combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|
Yang J.C.-H.; Sequist L.V.; Geater S.L.; Tsai C.-M.; Mok T.S.K.; Schuler M.; Yamamoto N.; CHONG-JEN YU; Ou S.H.I.; Zhou C.; Massey D.; Zazulina V.; Wu Y.-L. |
| 臺大學術典藏 |
2022-06-27T07:00:26Z |
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
|
Hsu C.-H.; Tseng C.-H.; Chiang C.-J.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; CHONG-JEN YU; Tsai Y.-H.; Chen J.-S.; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; Lee W.-C.; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:23Z |
First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer the ASPIRATION study
|
Park K.; CHONG-JEN YU; Kim S.-W.; Lin M.-C.; Sriuranpong V.; Tsai C.-M.; Lee J.-S.; Kang J.-H.; Chan K.C.A.; Perez-Moreno P.; Button P.; Ahn M.-J.; Mok T. |
| 臺大學術典藏 |
2022-06-27T07:00:13Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; CHONG-JEN YU; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. |
| 臺大學術典藏 |
2022-06-27T07:00:11Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Paz-Ares L.; Wolf J.; Geater S.L.; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2022-06-27T06:59:45Z |
Final Overall Survival and Other Efficacy and Safety Results From ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged NSCLC
|
Nishio M.; Felip E.; Orlov S.; Park K.; CHONG-JEN YU; Tsai C.-M.; Cobo M.; McKeage M.; Su W.-C.; Mok T.; Scagliotti G.V.; Spigel D.R.; Viraswami-Appanna K.; Chen Z.; Passos V.Q.; Shaw A.T. |
| 臺大學術典藏 |
2022-06-27T06:59:36Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2022-05-02T02:52:44Z |
Fatigue experience and coping strategies in Taiwanese lung cancer patients receiving chemotherapy
|
YUN-HSIANG LEE; Tsai Y.-F.; Lai Y.-H.; Tsai C.-M. |
| 臺大學術典藏 |
2022-04-28T08:06:47Z |
Fatigue experience and coping strategies in Taiwanese lung cancer patients receiving chemotherapy
|
Lee Y.-H.; Tsai Y.-F.; YEUR-HUR LAI; Tsai C.-M. |
| 臺大學術典藏 |
2022-03-09T03:12:24Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; HUEI-WEN CHEN; Yu S.-L.; Liu T.-W.; Chang G.-C. |
| 國立成功大學 |
2022 |
Non-protective immune imprint underlies failure of Staphylococcus aureus IsdB vaccine
|
Tsai, C.-M.;Caldera, J.R.;Hajam, I.A.;Chiang, A.W.T.;Tsai, C.-H.;Li, H.;D�ez, M.L.;Gonzalez, C.;Trieu, D.;Martins, G.A.;Underhill, D.M.;Arditi, M.;Lewis, N.E.;Liu, G.Y. |
| 臺大學術典藏 |
2021-11-03T05:24:54Z |
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup Analysis
|
Tan D.S.W.; Geater S.; CHONG-JEN YU; Tsai C.-M.; Hsia T.-C.; Chen J.; Lin M.-C.; Lu Y.; Sriuranpong V.; Yang C.-T.; Sen P.; Branle F.; Shi M.; Wu Y.-L. |
| 臺大學術典藏 |
2021-09-01T02:02:28Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; ANN-LII CHENG; Liu M.Y.; Chiang S.C.; Chen Y.M.; Luh K.T.; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 臺大學術典藏 |
2021-09-01T02:02:06Z |
A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma
|
Chen Y.-M.; Yu C.-J.; Yang C.-H.; Perng R.-P.; Tsai C.-M.; Shih J.-F.; ANN-LII CHENG; Lefresne F.; Barbier M.; Pouget J.-C.; Yang P.-C. |
| 臺大學術典藏 |
2021-08-24T06:05:06Z |
Survival of patients aged over 80 years after Austin-Moore hemiarthroplasty and bipolar hemiarthroplasty for femoral neck fractures
|
Lin C.-C.; Huang S.-C.; Ou Y.-K.; Liu Y.-C.; Tsai C.-M.; Chan H.-H.; CHEN-TI WANG |
| 臺大學術典藏 |
2021-08-03T01:43:31Z |
Comparative Study of Li-CO2and Na-CO2Batteries with Ru@CNT as a Cathode Catalyst
|
Thoka S;Tsai C.-M;Tong Z;Jena A;Wang F.-M;Hsu C.-C;Chang H;Hu S.-F;Liu R.-S.; Thoka S; Tsai C.-M; Tong Z; Jena A; Wang F.-M; Hsu C.-C; Chang H; Hu S.-F; Liu R.-S.; RU-SHI LIU |
| 臺大學術典藏 |
2021-05-26T03:35:12Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.; Tsai C.M.; Wang L.S.; Lee Y.C.; Chang C.J.; Lui L.T.; Yen S.H.; Hsu C.; Cheng A.L.; Liu M.Y.; Chiang S.C.; Chen Y.M.; KWEN-TAY LUH; Huang M.H.; Yang P.-C.; Perng R.-P. |
| 臺大學術典藏 |
2021-05-07T06:02:30Z |
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
|
Hsu C.-H.; Tseng C.-H.; CHUN-JU CHIANG; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; Lee W.-C.; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2021-05-07T06:02:29Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Tseng C.-H.;Chun-Ju Chiang;Tseng J.-S.;Yang T.-Y.;Hsu K.-H.;Chen K.-C.;Wang C.-L.;Chen C.-Y.;Yen S.H.;Tsai C.-M.;Huang M.-S.;Ho C.-C.;Yu C.-J.;Tsai Y.-H.;Chen J.-S.;Chou T.-Y.;Tsai M.-H.;Chen H.-Y.;Su K.-Y.;Chen J.J.W.;Chen H.-W.;Yu S.-L.;Liu T.-W.;Chang G.-C.; Tseng C.-H.; CHUN-JU CHIANG; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. |
| 臺大學術典藏 |
2021-05-02T03:49:12Z |
Experience from Asian centers in a named-patient-use program for afatinib in patients with advanced non-small-cell lung cancer who had progressed following prior therapies, including patients with uncommon EGFR mutations
|
Chang G.-C.; Lam D.C.-L.; Tsai C.-M.; Chen Y.-M.; JIN-YUAN SHIH; Aggarwal S.; Wang S.; Kim S.-W.; Kim Y.-C.; Wahid I.; Li R.; Lim D.W.-T.; Sriuranpong V.; Chan R.T.-T.; Lorence R.M.; Carriere P.; Raabe C.; Cseh A.; Park K. |
| 國立成功大學 |
2021 |
A novel score system of blood tests for differentiating Kawasaki disease from febrile children
|
Tsai, C.-M.;Chu, Chu C.-H.;Liu, X.;Weng, K.-P.;Liu, S.-F.;Huang, Y.-H.;Kuo, H.-C. |
| 臺大學術典藏 |
2020-12-02T02:36:06Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Yang C.H.;Tsai C.M.;Wang L.S.;Lee Y.C.;Chang C.J.;Lui L.T.;Yen S.H.;Hsu C.;Cheng A.L.;Liu M.Y.;Chiang S.C.;Chen Y.M.;Luh K.T.;Huang M.H.;Pan-Chyr Yang;Perng R.-P.; Yang C.H.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-12-02T02:34:52Z |
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients
|
Chang G.-C.; Tsai C.-M.; Chen K.-C.; Yu C.-J.; Shih J.-Y.; Yang T.-Y.; Lin C.-P.; Hsu J.-Y.; Chiu C.-H.; Perng R.-P.; Pan-Chyr Yang; Yang C.-H.; Chang G.-C.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:34:44Z |
A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma
|
Chen Y.-M.; Yu C.-J.; Yang C.-H.; Perng R.-P.; Tsai C.-M.; Shih J.-F.; Cheng A.-L.; Lefresne F.; Barbier M.; Pouget J.-C.; Pan-Chyr Yang; Chen Y.-M.; PAN-CHYR YANG et al. |
| 臺大學術典藏 |
2020-12-02T02:34:00Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Yang J.C.H.; Shih J.-Y.; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L.; Sequist L.V.; Dudek A.Z.; Shahidi M.; Cong X.J.; Lorence R.M.; PAN-CHYR YANG; Miller V.A. |
| 臺大學術典藏 |
2020-12-02T02:33:44Z |
A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)
|
Shi Y.;Au J.S.-K.;Thongprasert S.;Srinivasan S.;Tsai C.-M.;Khoa M.T.;Heeroma K.;Itoh Y.;Cornelio G.;PAN-CHYR YANG; Shi Y.; Au J.S.-K.; Thongprasert S.; Srinivasan S.; Tsai C.-M.; Khoa M.T.; Heeroma K.; Itoh Y.; Cornelio G.; PAN-CHYR YANG |
| 臺大學術典藏 |
2020-11-19T08:19:18Z |
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status
|
Hsu C.-H.;Tseng C.-H.;Chiang C.-J.;Hsu K.-H.;Tseng J.-S.;Chen K.-C.;Wang C.-L.;Chen C.-Y.;Yen S.-H.;Chiu C.-H.;Huang M.-S.;Yu C.-J.;Tsai Y.-H.;Chen J.-S.;Tsai C.-M.;Chou T.-Y.;Lin K.-C.;Tsai M.-H.;Wen-Chung Lee;Ku H.-Y.;Liu T.-W.;Yang T.-Y.;Chang G.-C.; Hsu C.-H.; Tseng C.-H.; Chiang C.-J.; Hsu K.-H.; Tseng J.-S.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.-H.; Chiu C.-H.; Huang M.-S.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Tsai C.-M.; Chou T.-Y.; Lin K.-C.; Tsai M.-H.; WEN-CHUNG LEE; Ku H.-Y.; Liu T.-W.; Yang T.-Y.; Chang G.-C. |
| 臺大學術典藏 |
2020-08-13T06:33:49Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Miller V.A.; Yang P.-C.; Lorence R.M.; Cong X.J.; Shahidi M.; Dudek A.Z.; Sequist L.V.; Yang J.C.H.; JIN-YUAN SHIH; Su W.-C.; Hsia T.-C.; Tsai C.-M.; Ou S.H.I.; Yu C.-J.; Chang G.-C.; Ho C.-L. |
| 臺大學術典藏 |
2020-08-13T06:33:42Z |
Epidermal growth factor receptor tyrosine Kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations
|
Chuang C.-Y.; Yu-Wung Yeh D.; Lin C.-B.; Hsiao S.-H.; Lin Y.-C.; Ho C.-L.; Hsia T.-C.; Wu M.-F.; Lai C.-L.; Lee K.-Y.; Wang C.-C.; Chiu C.-H.; Yang C.-T.; JIN-YUAN SHIH; Huang M.-S.; Su W.-C.; Lai R.-S.; Chang F.-K.; Tsai C.-M.; Perng R.-P.; Chih-Hsin Yang J. |
| 臺大學術典藏 |
2020-08-12T06:35:48Z |
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients
|
Chang G.-C.; Tsai C.-M.; Chen K.-C.; CHONG-JEN YU; Shih J.-Y.; Yang T.-Y.; Lin C.-P.; Hsu J.-Y.; Chiu C.-H.; Perng R.-P.; Yang P.-C.; Yang C.-H. |
| 臺大學術典藏 |
2020-08-12T06:35:46Z |
A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma
|
Chen Y.-M.; CHONG-JEN YU; Yang C.-H.; Perng R.-P.; Tsai C.-M.; Shih J.-F.; Cheng A.-L.; Lefresne F.; Barbier M.; Pouget J.-C.; Yang P.-C. |
| 臺大學術典藏 |
2020-08-12T06:35:26Z |
Different efficacies of erlotinib and gefitinib in Taiwanese patients with advanced non-small cell lung cancer: A retrospective multicenter study
|
Fan W.-C.;Chong-Jen Yu;Tsai C.-M.;Huang M.-S.;Lai C.-L.;Hsia T.-C.;Tien Y.-J.;Huang S.-F.;Wu C.-H.;Chou K.-T.;Lee Y.-C.;Perng R.-P.;Chen Y.-M.; Fan W.-C.; CHONG-JEN YU; Tsai C.-M.; Huang M.-S.; Lai C.-L.; Hsia T.-C.; Tien Y.-J.; Huang S.-F.; Wu C.-H.; Chou K.-T.; Lee Y.-C.; Perng R.-P.; Chen Y.-M. |
| 臺大學術典藏 |
2020-08-12T06:34:35Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Yu S.-L.; Chen H.-W.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; CHONG-JEN YU; Ho C.-C.; Huang M.-S.; Tsai C.-M.; Yen S.H.; Chen C.-Y.; Wang C.-L.; Chen K.-C.; Hsu K.-H.; Tseng C.-H.;Chiang C.-J.;Tseng J.-S.;Yang T.-Y.;Hsu K.-H.;Chen K.-C.;Wang C.-L.;Chen C.-Y.;Yen S.H.;Tsai C.-M.;Huang M.-S.;Ho C.-C.;Chong-Jen Yu;Tsai Y.-H.;Chen J.-S.;Chou T.-Y.;Tsai M.-H.;Chen H.-Y.;Su K.-Y.;Chen J.J.W.;Chen H.-W.;Yu S.-L.;Liu T.-W.;Chang G.-C.; Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Chang G.-C.; Liu T.-W. |
| 臺大學術典藏 |
2020-08-12T06:34:32Z |
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
|
Geater S.L.; Wolf J.; Paz-Ares L.; Soria J.-C.; Tan D.S.W.; Chiari R.; Wu Y.-L.; Soria J.-C.;Tan D.S.W.;Chiari R.;Wu Y.-L.;Paz-Ares L.;Wolf J.;Geater S.L.;Orlov S.;Cortinovis D.;Chong-Jen Yu;Hochmair M.;Cortot A.B.;Tsai C.-M.;Moro-Sibilot D.;Campelo R.G.;Mcculloch T.;Sen P.;Dugan M.;Pantano S.;Branle F.;Massacesi C.;De Castro G.;Jr; Orlov S.; Cortinovis D.; CHONG-JEN YU; Hochmair M.; Cortot A.B.; Tsai C.-M.; Moro-Sibilot D.; Campelo R.G.; McCulloch T.; Sen P.; Dugan M.; Pantano S.; Branle F.; Massacesi C.; de Castro G.; Jr |
| 臺大學術典藏 |
2020-07-21T06:46:24Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; CHAO-CHI HO; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. |
| 臺大學術典藏 |
2020-06-30T08:09:58Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Tseng C.-H.;Chiang C.-J.;Tseng J.-S.;Yang T.-Y.;Hsu K.-H.;Chen K.-C.;Wang C.-L.;Chen C.-Y.;Yen S.H.;Tsai C.-M.;Huang M.-S.;Ho C.-C.;Yu C.-J.;Tsai Y.-H.;Chen J.-S.;Chou T.-Y.;Tsai M.-H.;Chen H.-Y.;Kang-Yi Su;Chen J.J.W.;Chen H.-W.;Yu S.-L.;Liu T.-W.;Chang G.-C.; Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H.; Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; KANG-YI SU; Chen J.J.W.; Chen H.-W.; Yu S.-L.; Liu T.-W.; Chang G.-C. |
| 臺大學術典藏 |
2020-06-17T03:01:32Z |
EGFR mutation, smoking, and gender in advanced lung adenocarcinoma
|
Chen K.-C.; Wang C.-L.; Chen C.-Y.; Yen S.H.; Tsai C.-M.; Huang M.-S.; Ho C.-C.; Yu C.-J.; Tsai Y.-H.; Chen J.-S.; Chou T.-Y.; Tsai M.-H.; Chen H.-Y.; Su K.-Y.; Chen J.J.W.; Chen H.-W.; SUNG-LIANG YU; Liu T.-W.; Chang G.-C.; Tseng C.-H.;Chiang C.-J.;Tseng J.-S.;Yang T.-Y.;Hsu K.-H.;Chen K.-C.;Wang C.-L.;Chen C.-Y.;Yen S.H.;Tsai C.-M.;Huang M.-S.;Ho C.-C.;Yu C.-J.;Tsai Y.-H.;Chen J.-S.;Chou T.-Y.;Tsai M.-H.;Chen H.-Y.;Su K.-Y.;Chen J.J.W.;Chen H.-W.;Sung-Liang Yu;Liu T.-W.;Chang G.-C.; Tseng C.-H.; Chiang C.-J.; Tseng J.-S.; Yang T.-Y.; Hsu K.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:31Z |
Gemcitabine and cisplatin in a multimodality treatment for locally advanced non-small cell lung cancer
|
Perng R.-P.; Chih-Hsin Yang;Tsai C.M;Wang L.S;Lee Y.C;Chang C.J;Lui L.T;Yen S.H;Hsu C;Cheng A.L;Liu M.Y;Chiang S.C;Chen Y.M;Luh K.T;Huang M.H;Yang P.-C;Perng R.-P.; CHIH-HSIN YANG; Tsai C.M; Wang L.S; Lee Y.C; Chang C.J; Lui L.T; Yen S.H; Hsu C; Cheng A.L; Liu M.Y; Chiang S.C; Chen Y.M; Luh K.T; Huang M.H; Yang P.-C |
| 臺大學術典藏 |
2020-05-26T09:27:27Z |
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients
|
Chang G.-C;Tsai C.-M;Chen K.-C;Yu C.-J;Shih J.-Y;Yang T.-Y;Lin C.-P;Hsu J.-Y;Chiu C.-H;Perng R.-P;Yang P.-C;Chih-Hsin Yang; Chang G.-C; Tsai C.-M; Chen K.-C; Yu C.-J; Shih J.-Y; Yang T.-Y; Lin C.-P; Hsu J.-Y; Chiu C.-H; Perng R.-P; Yang P.-C; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:27:26Z |
Revisit of 1997 TNM staging system - Survival analysis of 1112 lung cancer patients in Taiwan
|
Perng R.-P;Chen C.-Y;Chang G.-C;Hsia T.-C;Hsu N.-Y;Tsai Y.-H;Tsai C.-M;Chih-Hsin Yang;Chen Y.-M;Yu C.-J;Lee J.-J;Hsu H.-S;Yu C.-T;Kao E.-L;Chiu C.-H.; Perng R.-P; Chen C.-Y; Chang G.-C; Hsia T.-C; Hsu N.-Y; Tsai Y.-H; Tsai C.-M; CHIH-HSIN YANG; Chen Y.-M; Yu C.-J; Lee J.-J; Hsu H.-S; Yu C.-T; Kao E.-L; Chiu C.-H. |
| 臺大學術典藏 |
2020-05-26T09:27:25Z |
A phase II study of oral vinorelbine in combination with cisplatin conducted in Taiwan in patients with unresectable localized or metastatic non-small cell lung carcinoma
|
Chen Y.-M;Yu C.-J;Chih-Hsin Yang;Perng R.-P;Tsai C.-M;Shih J.-F;Cheng A.-L;Lefresne F;Barbier M;Pouget J.-C;Yang P.-C.; Chen Y.-M; Yu C.-J; CHIH-HSIN YANG; Perng R.-P; Tsai C.-M; Shih J.-F; Cheng A.-L; Lefresne F; Barbier M; Pouget J.-C; Yang P.-C. |
| 臺大學術典藏 |
2020-05-26T09:27:07Z |
Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial
|
Miller V.A.;Yang P.-C;Lorence R.M;Cong X.J;Shahidi M;Dudek A.Z;Sequist L.V;Ho C.-L;Chang G.-C;Yu C.-J;Ou S.H.I;Tsai C.-M;Hsia T.-C;Su W.-C;Shih J.-Y;Chih-Hsin Yang; CHIH-HSIN YANG; Shih J.-Y; Su W.-C; Hsia T.-C; Tsai C.-M; Ou S.H.I; Yu C.-J; Chang G.-C; Ho C.-L; Sequist L.V; Dudek A.Z; Shahidi M; Cong X.J; Lorence R.M; Yang P.-C; Miller V.A. |
